A new targeting approach for breast cancer gene therapy using the human fatty acid synthase promoter

References

• McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000; 321: 624–8
   PubMed Web of Science ®Google Scholar
• Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 1996; 23: 154–8
   PubMed Web of Science ®Google Scholar
• Matono S, Tanaka T, Sueyoshi S, Yamana H, Fujita H, Shirouzu K. Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer. Int J Oncol 2003; 23: 1309–15
   PubMed Web of Science ®Google Scholar
• Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763–71
   PubMed Web of Science ®Google Scholar
• Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999; 17: 2180–9
   PubMed Web of Science ®Google Scholar
• Yu L, Yamamoto N, Kadomatsu K, Muramatsu S, Matsubara S, Sakiyama S, et al. Midkine promoter can mediate transcriptional activation of a fused suicide gene in a broader range of human breast cancer compared with c-erbB-2 promoter. Oncology 2004; 66: 143–9
   PubMed Web of Science ®Google Scholar
• Li X, Zhang J, Gao H, Vieth E, Bae KH, Zhang YP, et al. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by α-lactalbumin promoter. Mol Cancer Ther 2005; 4: 1850–9
   PubMed Web of Science ®Google Scholar
• Breidenbach M, Rein DT, Schondorf T, Khan KN, Herrmann I, Schmidt T et al. A new targeting approach for breast cancer gene therapy using the Heparanase promoter. Cancer Lett 2005;
   PubMed Web of Science ®Google Scholar
• Semenkovich CF, Coleman T, Fiedorek FT, Jr. Human fatty acid synthase mRNA: Tissue distribution, genetic mapping, and kinetics of decay after glucose deprivation. J Lipid Res 1995; 36: 1507–21
   PubMed Web of Science ®Google Scholar
• Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996; 77: 474–82
   PubMed Web of Science ®Google Scholar
• Milgraum LZ, Witers LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997; 3: 2115–20
   PubMed Web of Science ®Google Scholar
• Gansler TS, Hardman W, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997; 28: 686–92
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002; 98: 19–22
   PubMed Web of Science ®Google Scholar
• Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 1997; 150: 201–8
   PubMed Web of Science ®Google Scholar
• Yahagi N, Shimano H, Hasegawa K, Ohashi K, Matsuzaka T, Najima Y, et al. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 2005; 41: 1316–22
   PubMed Web of Science ®Google Scholar
• Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000; 31: 1068–73
   PubMed Web of Science ®Google Scholar
• Innocenzi D, Alo PL, Balzani A, Sebastiani V, Silipo V, La Torre G, et al. Fatty acid synthase expression in melanoma. J Cutan Pathol 2003; 30: 23–8
   PubMed Web of Science ®Google Scholar
• Menendez JA, Decker JP, Lupu R. In support of fatty acid synthase (FAS) as a metabolic oncogene: Extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J Cell Biochem 2005; 94: 1–4
   PubMed Web of Science ®Google Scholar
• O'Connell MJ, McInerney JO. Adaptive evolution of the human fatty acid synthase gene: Support for the cancer selection and fat utilization hypotheses?. Gene 2005; 360: 151–9
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: From anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz) 2004; 52: 414–26
   PubMed Web of Science ®Google Scholar
• Alo PL, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S, et al. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 1999; 85: 35–40
   PubMed Web of Science ®Google Scholar
• Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA, et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA. 2000; 97: 3450–4
   PubMed Web of Science ®Google Scholar
• Jayakumar A, Tai MH, Huang WY, al-Feel W, Hsu M, Abu-Elheiga L, et al. Human fatty acid synthase: Properties and molecular cloning. Proc Natl Acad Sci USA. 1995; 92: 8695–9
   PubMed Web of Science ®Google Scholar
• Hsu MH, Chirala SS, Wakil SJ. Human Fatty acid Synthase Gene: Evidence for the presence of two promoters and their functional interaction. J Biol Chem 1996; 271: 13584–92
   PubMed Web of Science ®Google Scholar
• Menendez JA, Vellon L, Lupu R. Targeting fatty acid synthase-driven lipid rafts: A novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 2005; 64: 997–1001
   PubMed Web of Science ®Google Scholar
• Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta 1994; 1198: 165–84
   PubMed Web of Science ®Google Scholar
• Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999; 17: 2180–9
   PubMed Web of Science ®Google Scholar
• Miyashiro I, Kaname T, Shin E, Wakasugi E, Monden T, Takatsuka Y, et al. Midkine expression in human breast cancers: Expression of truncated form. Breast Cancer Res Treat 1997; 43: 1–6
   PubMed Web of Science ®Google Scholar
• Garver RI, Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG, et al. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994; 74: 1584–90
   PubMed Web of Science ®Google Scholar
• Nicholas TW, Read SB, Burrows FJ, Kruse CA. Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol Histopathol 2003; 18: 495–507
   PubMed Web of Science ®Google Scholar